Analysts cut fair value for Chugai Pharmaceutical stock to JPY 8,870

Analysts cut fair value for Chugai Pharmaceutical from JPY 9,323.00 to JPY 8,870.00 on October 1, 2026, according to Simply Wall St. Chugai Pharmaceutical stock was trading at EUR 34.40 at Lang & Schwarz on October 7, 2026 at 10:35 a.m. CEST, up 0.41 percent from the prior close of EUR 34.26.

Revenue grows in fiscal 2026

Chugai reported revenue of JPY 341.58 billion for the second quarter of fiscal 2026, a 17.80 percent increase from the same period a year earlier, while net income reached JPY 116.33 billion, according to JPX Market Explorer. The result gives the valuation debate a concrete operating base, even as the lower fair value points to tighter expectations for future earnings multiples.

Chugai's investor-relations page identifies October 27, 2026 as the date for third-quarter results covering January through September 2026, giving the market a scheduled test for the company's full-year trajectory.

Pipeline reset carries a risk

On September 28, 2026, Chugai Pharmaceutical said Roche would discontinue obesity development of emugrobart and return the rights. Chugai said it had begun preparations to resume development for spinal muscular atrophy and was considering out-licensing opportunities.

The announcement changes the asset's role rather than changing the fiscal 2026 forecast, which Chugai said would not be affected. For investors, the key tension is measurable: second-quarter revenue growth of 17.80 percent sits beside a lower fair value of JPY 8,870.00, making pipeline execution important for the next valuation update.

South Korea adds a growth option

Chugai announced on September 30, 2026 that it would establish Chugai Pharma Korea, a wholly owned subsidiary planned for incorporation on November 2, 2026, according to Chugai Pharmaceutical. The unit is intended to build in-house capabilities for regulatory approvals, imports and sales ahead of future product launches.

Euro quote edges higher

At Lang & Schwarz, Chugai Pharmaceutical stock was trading at EUR 34.40 on October 7, 2026 at 10:35 a.m. CEST, plus 0.41 percent versus the prior close of EUR 34.26 on October 6, 2026. The Tokyo-listed shares were last quoted at JPY 6,101.00 on October 7, 2026 at 3:30 p.m. JST, against a 52-week range of JPY 5,974.00 to JPY 10,700.00.

The further course of trading is shown by the continuously updated real-time quote of Chugai Pharmaceutical stock.

More news and analyses on Chugai Pharmaceutical stock